944 related articles for article (PubMed ID: 22583478)
1. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.
Rivas MA; Venturutti L; Huang YW; Schillaci R; Huang TH; Elizalde PV
Breast Cancer Res; 2012 May; 14(3):R77. PubMed ID: 22583478
[TBL] [Abstract][Full Text] [Related]
2. Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.
Izzo F; Mercogliano F; Venturutti L; Tkach M; Inurrigarro G; Schillaci R; Cerchietti L; Elizalde PV; Proietti CJ
Breast Cancer Res; 2014 Dec; 16(6):491. PubMed ID: 25479686
[TBL] [Abstract][Full Text] [Related]
3. MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells.
Zhao Y; Li Y; Lou G; Zhao L; Xu Z; Zhang Y; He F
PLoS One; 2012; 7(6):e39102. PubMed ID: 22723937
[TBL] [Abstract][Full Text] [Related]
4. MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer.
Luo Q; Li X; Li J; Kong X; Zhang J; Chen L; Huang Y; Fang L
Int J Oncol; 2013 Oct; 43(4):1212-8. PubMed ID: 23900351
[TBL] [Abstract][Full Text] [Related]
5. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis.
Ma L; Young J; Prabhala H; Pan E; Mestdagh P; Muth D; Teruya-Feldstein J; Reinhardt F; Onder TT; Valastyan S; Westermann F; Speleman F; Vandesompele J; Weinberg RA
Nat Cell Biol; 2010 Mar; 12(3):247-56. PubMed ID: 20173740
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer.
Luo Q; Wei C; Li X; Li J; Chen L; Huang Y; Song H; Li D; Fang L
Oncol Rep; 2014 Mar; 31(3):1096-102. PubMed ID: 24402230
[TBL] [Abstract][Full Text] [Related]
7. MiR-492 contributes to cell proliferation and cell cycle of human breast cancer cells by suppressing SOX7 expression.
Shen F; Cai WS; Feng Z; Li JL; Chen JW; Cao J; Xu B
Tumour Biol; 2015 Mar; 36(3):1913-21. PubMed ID: 25407488
[TBL] [Abstract][Full Text] [Related]
8. Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer.
Cochrane DR; Jacobsen BM; Connaghan KD; Howe EN; Bain DL; Richer JK
Mol Cell Endocrinol; 2012 May; 355(1):15-24. PubMed ID: 22330642
[TBL] [Abstract][Full Text] [Related]
9. c-Myc Represses Tumor-Suppressive microRNAs, let-7a, miR-16 and miR-29b, and Induces Cyclin D2-Mediated Cell Proliferation in Ewing's Sarcoma Cell Line.
Kawano M; Tanaka K; Itonaga I; Iwasaki T; Tsumura H
PLoS One; 2015; 10(9):e0138560. PubMed ID: 26393798
[TBL] [Abstract][Full Text] [Related]
10. Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3.
Béguelin W; Díaz Flaqué MC; Proietti CJ; Cayrol F; Rivas MA; Tkach M; Rosemblit C; Tocci JM; Charreau EH; Schillaci R; Elizalde PV
Mol Cell Biol; 2010 Dec; 30(23):5456-72. PubMed ID: 20876300
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2.
Pierson-Mullany LK; Lange CA
Mol Cell Biol; 2004 Dec; 24(24):10542-57. PubMed ID: 15572662
[TBL] [Abstract][Full Text] [Related]
12. A regulatory loop involving miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer invasion and metastasis.
Kong LM; Liao CG; Zhang Y; Xu J; Li Y; Huang W; Zhang Y; Bian H; Chen ZN
Cancer Res; 2014 Jul; 74(14):3764-78. PubMed ID: 24906624
[TBL] [Abstract][Full Text] [Related]
13. Progestin drives breast cancer growth by inducing p21(CIP1) expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2.
Diaz Flaqué MC; Vicario R; Proietti CJ; Izzo F; Schillaci R; Elizalde PV
Steroids; 2013 Jun; 78(6):559-67. PubMed ID: 23178160
[TBL] [Abstract][Full Text] [Related]
14. miR-519d-mediated downregulation of STAT3 suppresses breast cancer progression.
Deng X; Zhao Y; Wang B
Oncol Rep; 2015 Oct; 34(4):2188-94. PubMed ID: 26238950
[TBL] [Abstract][Full Text] [Related]
15. Heregulin Co-opts PR Transcriptional Action Via Stat3 Role As a Coregulator to Drive Cancer Growth.
Proietti CJ; Izzo F; Díaz Flaqué MC; Cordo Russo R; Venturutti L; Mercogliano MF; De Martino M; Pineda V; Muñoz S; Guzmán P; Roa JC; Schillaci R; Elizalde PV
Mol Endocrinol; 2015 Oct; 29(10):1468-85. PubMed ID: 26340407
[TBL] [Abstract][Full Text] [Related]
16. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways.
Carnevale RP; Proietti CJ; Salatino M; Urtreger A; Peluffo G; Edwards DP; Boonyaratanakornkit V; Charreau EH; Bal de Kier Joffé E; Schillaci R; Elizalde PV
Mol Endocrinol; 2007 Jun; 21(6):1335-58. PubMed ID: 17440047
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters.
Giulianelli S; Vaqué JP; Soldati R; Wargon V; Vanzulli SI; Martins R; Zeitlin E; Molinolo AA; Helguero LA; Lamb CA; Gutkind JS; Lanari C
Cancer Res; 2012 May; 72(9):2416-27. PubMed ID: 22396492
[TBL] [Abstract][Full Text] [Related]
18. Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells.
Labriola L; Salatino M; Proietti CJ; Pecci A; Coso OA; Kornblihtt AR; Charreau EH; Elizalde PV
Mol Cell Biol; 2003 Feb; 23(3):1095-111. PubMed ID: 12529413
[TBL] [Abstract][Full Text] [Related]
19. Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein.
Xiong J; Du Q; Liang Z
Oncogene; 2010 Sep; 29(35):4980-8. PubMed ID: 20562918
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-195 inhibits the proliferation of human glioma cells by directly targeting cyclin D1 and cyclin E1.
Hui W; Yuntao L; Lun L; WenSheng L; ChaoFeng L; HaiYong H; Yueyang B
PLoS One; 2013; 8(1):e54932. PubMed ID: 23383003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
